Trials / Terminated
TerminatedNCT01617213
Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
Autologous Peripheral Blood Stem Cell Transplantation and Maintenance Lenalidomide After High-dose Melphalan for Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- University of Virginia · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melphalan | 200 mg/m2/IV |
| DRUG | Lenalidomide | 10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2015-04-01
- First posted
- 2012-06-12
- Last updated
- 2013-06-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01617213. Inclusion in this directory is not an endorsement.